{
    "id": "ba6ae57f-0729-4c8d-afc8-1e99a5a99871",
    "indications": {
        "text": "vitrakvi indicated treatment adult pediatric patients solid tumors : neurotrophic receptor tyrosine kinase ( ntrk ) gene fusion without known acquired resistance mutation , metastatic surgical resection likely result severe morbidity , satisfactory alternative treatments progressed following treatment . select patients therapy based fda-approved test [ ( 2.1 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "select patients treatment vitrakvi based presence ntrk gene fusion ( 2.1 , 14 ) . recommended adult pediatric patients body surface area 1 meter-squared greater : 100 mg orally twice daily ( 2.2 ) recommended pediatric patients body surface area less 1 meter-squared : 100 mg/m 2 orally twice daily ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "LAROTRECTINIB",
            "code": "PF9462I9HX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14723"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "SODIUM PHOSPHATE",
            "code": "SE337SVY37",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "POTASSIUM SORBATE",
            "code": "1VPU26JZZ4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77868"
        },
        {
            "name": "ADRABETADEX",
            "code": "8W6Q67R6NX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15146"
        },
        {
            "name": "HYDROXYPROPYL BETADEX",
            "code": "1I96OHX6EK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_195327"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        }
    ],
    "organization": "Bayer HealthCare Pharmaceuticals Inc.",
    "name": "VITRAKVI",
    "effectiveTime": "20250430",
    "indications_original": "VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:\n                  \n                  \n                     \n                        have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,\n                     \n                     \n                        are metastatic or where surgical resection is likely to result in severe morbidity, and \n                     \n                     \n                        have no satisfactory alternative treatments or that have progressed following treatment.\n                     \n                  \n                  \n                     Select patients for therapy based on an FDA-approved test [see Dosage and Administration (2.1)].",
    "contraindications_original": "Select patients for treatment with VITRAKVI based on the presence of a NTRK gene fusion ( 2.1 , 14 ). Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of 1 Meter-Squared or greater: 100 mg orally twice daily ( 2.2 ) Recommended Dosage in Pediatric Patients with Body Surface Area of Less Than 1 Meter-Squared: 100 mg/m 2 orally twice daily ( 2.2 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "VITRAKVI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14723"
        }
    ]
}